Aptevo Therapeutics (APVO) Hits New 12-Month High at $4.56

Aptevo Therapeutics Inc (NASDAQ:APVO) reached a new 52-week high on Tuesday . The company traded as high as $4.56 and last traded at $4.24, with a volume of 118000 shares. The stock had previously closed at $4.23.

A number of equities research analysts have weighed in on the company. ValuEngine downgraded Aptevo Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, November 10th. Piper Jaffray Companies restated an “overweight” rating and issued a $6.00 target price on shares of Aptevo Therapeutics in a research report on Thursday, October 5th.

The stock has a market cap of $99.43 and a price-to-earnings ratio of -2.55. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.67 and a current ratio of 7.76.

In related news, VP Randy Joe Maddux purchased 25,000 shares of the company’s stock in a transaction on Wednesday, November 15th. The shares were bought at an average price of $2.76 per share, with a total value of $69,000.00. Following the completion of the acquisition, the vice president now owns 25,000 shares of the company’s stock, valued at $69,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 15.60% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP increased its holdings in shares of Aptevo Therapeutics by 8.0% in the second quarter. Dimensional Fund Advisors LP now owns 1,056,729 shares of the biotechnology company’s stock valued at $2,187,000 after buying an additional 78,109 shares in the last quarter. Precept Management LLC bought a new position in shares of Aptevo Therapeutics in the second quarter valued at $1,210,000. Finally, Legal & General Group Plc increased its holdings in shares of Aptevo Therapeutics by 11,751.3% in the second quarter. Legal & General Group Plc now owns 393,701 shares of the biotechnology company’s stock valued at $815,000 after buying an additional 390,379 shares in the last quarter. 32.13% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.chaffeybreeze.com/2018/01/04/aptevo-therapeutics-apvo-hits-new-12-month-high-at-4-56.html.

About Aptevo Therapeutics

Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply